



Perspectives on using *Physcomitrella Patens* as an alternative production platform for Thapsigargin and other Terpenoid drug candidates

Simonsen, Henrik Toft; Drew, Damian Paul; Lunde, Christina

Published in:
Perspectives in Medicinal Chemistry

Publication date:
2009

Document version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Simonsen, H. T., Drew, D. P., & Lunde, C. (2009). Perspectives on using *Physcomitrella Patens* as an alternative production platform for Thapsigargin and other Terpenoid drug candidates. *Perspectives in Medicinal Chemistry*, 3, 1-6. <http://www.la-press.com/perspectives-on-using-physcomitrellanbsp-patens-as-an-alternative-prod-a1343>

Perspectives on Using *Physcomitrella Patens* as an Alternative Production Platform for Thapsigargin and Other Terpenoid Drug Candidates

Henrik Toft Simonsen, Damian Paul Drew and Christina Lunde

VKR Research Centre Pro-Active Plants, Department of Plant Biology and Biotechnology, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark.

Abstract: To overcome the potential future demand for terpenoids used as drugs, a new production platform is currently being established in our laboratory. The moss *Physcomitrella* has been chosen as the candidate organism for production of drug candidates based on terpenoids derived from plants, with a primary focus on the sesquiterpene lactone, thapsigargin. This drug candidate and other candidates/drugs with sesquiterpene skeleton are difficult to obtain by chemical synthesis due to their large number of chiral centers. Furthermore, they are not available in sufficient amounts from their original plant. The requirement for a new production system to meet the potential market demand for these compounds is not only obvious, but also essential if sufficient quantities of the drug candidates are to be available for the potential therapeutic use.

Keywords: *physcomitrella*, thapsigargin, drug production, sesquiterpene

Biography: Henrik Toft Simonsen is an associate professor and research group leader at the VKR Research Centre Pro-Active Plants, Department of Plant Biology and Biotechnology, Faculty of Life Sciences, University of Copenhagen. He graduated as a pharmacist in 1998 from the faculty of Pharmaceutical Sciences, University of Copenhagen, and received his PhD in 2002 in Natural product Chemistry and Ethnopharmacology from the same place. From 2002 to 2004 Henrik worked at the Department of Chemistry, university of Cambridge, where he along with Dr. Leeper and co-workers completed the biosynthesis of Prodigiosin from the bacteria genera *Serratia*. His research has mainly been devoted to the biosynthesis, biochemistry, and spectroscopy of bioactive metabolites (terpenoids, phytotoxins, antibiotics, mycotoxins, fungicides, phytoalexins) produced by bacteria or plants. He is the leader of a new research group devoted to the elucidation of biosynthetic pathways of terpenoids. Henrik received the Danish Research Foundation's Young Elite Researchers Award in 2007/8 for his initiative on sesquiterpene biosynthesis.



Biography: Damian Drew is a post doc. in the VKR Research Centre Pro-Active Plants, Department of Plant Biology and Biotechnology, Faculty of Life Sciences, University of Copenhagen. He graduated at the top of his class from the University of South Australia with a Bachelor of Medical and Pharmaceutical Biotechnology, and also received a First Class Honours Degree. Damian completed his PhD in Molecular Biology at the Australian Center for Plant Functional Genomics, Adelaide University, while undertaking research into molecular mechanisms behind abiotic stress resistance in *Physcomitrella patens*, including biochemical characterization enzymes involved in oxidative stress responses, and structure-function investigations of membrane-bound sodium transporters. His current research interests include the characterization of the biosynthesis pathways of bioactive isoprenoids in plants, and the development of *Physcomitrella* as a bio-factory for bioactive compounds.



Biography: Christina Lunde is an Associate Professor at Institute of Plant Biology and Biotechnology at the Faculty of Life Sciences of the University of Copenhagen. She graduated from the University of Copenhagen in 1997 with a master degree in Biology after having completed her master project at Carlsberg Research Centre. Her PhD was completed at the Royal Danish Agricultural University and the research area was photosynthesis, and in particular how plants adapt to a ever changing light environment. After completing a 2-year post doc at the Australian Centre for Plant Functional Genomics, Adelaide University, Christina returned to the University of Copenhagen and is now mainly focusing on identifying novel genes conferring abiotic stress resistance in *Physcomitrella patens* and developing *Physcomitrella* into an ideal production host of proteins and secondary plant metabolites. Christina received the Danish Research Foundation's Young Elite Researchers Award in 2007/8 for her work.



Introduction

Plant cells are capable of producing an overwhelming variety of secondary metabolites, both in terms of complexity and quantity. These small organic molecules allow plants to cope with various types of stress,

Correspondence: Henrik Toft Simonsen, Tel: +45 35333723; Email: hts@life.ku.dk



Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the Creative Commons Attribution By licence. For further information go to: <http://creativecommons.org/licenses/by/3.0/>.

and often have biological activities beneficial to humans that make them of high commercial interest to the biotechnology industry.¹ Attempts have been made to make this overwhelming variety of compounds economically accessible by introducing the biosynthesis pathways of interesting natural products from higher plants into other organisms, for example yeast cultures.² This perspective discusses the benefits of a recently established production organism, the moss *Physcomitrella patens*, as a host for the production of terpenoids.

Plants containing pharmaceutically active natural products have been used worldwide in folk medicine since at least 4000 BC.³ More than 80,000 of the 250,000 known species of higher plant are used in medicine,⁴ and since some of these plants are threatened by extinction, much effort has been put into identifying the active compounds before their natural source disappears. The plants have often been used without knowing the exact mechanism by which the active compound exerts its effect. This is still true for several well-known chemical groupings of natural products, such as certain saponins, flavonoids and ginkgolides from *Ginkgo biloba* and *Panax ginseng*.⁵ However, for an increasing number of plants the pharmacological activity has been linked to one or more specific metabolites. Plant used in traditional medicine has been subjected to many different studies, ranging from antimicrobial,⁶ antimalarial,⁷ and to more advanced studies including clinical trials of either extracts or isolated compounds.⁸ A range of these isolated natural products have been pursued as pharmaceutical drugs, and a limited number have been successful.^{5,9} Many of these biologically active compounds from plants are isoprenoid molecules. At the end of 2006, more than 50,000 isoprenoid structures had been identified, of which many have known biological activities.¹⁰ Several of these isoprenoids have anti-tumor activity, including the well known Taxol (paclitaxel), which is originally extracted from pacific yew trees.⁹ Novel drugs are often in high demand, which leads to a high harvest pressure on the source of the drug such as the wild plants. As has already been seen in the cases of Taxol and the anti-malaria drug, artemisinin, one cannot only rely on the wild population for the supply of drugs.¹¹ There are several problematic issues regarding the collection of wild plants, and the fact that pharmaceutical companies need a secure and regular supply of plants if they are to be used for drug production, steers commercial

research away from “difficult” plants, which cannot be cultivated with high yields.¹² This is one of the major challenges for the development of the very promising drug candidate thapsigargin.¹³

A thapsigargin derived drug is currently undergoing clinical trials for the treatment of breast, kidney and prostate cancer.^{14,15} Thapsigargin induces apoptosis in mammalian cells by inhibiting the sarco/endoplasmic calcium ATPase (SERCA), resulting in an elevated cytoplasmic Ca^{2+} level, which eventually leads to the death of the cell.¹⁶ The crystal structure of the SERCA pump in which thapsigargin was bound inside the transmembrane pore showed large conformational changes when compared with the structure of SERCA with bound Ca^{2+} .¹⁷ This comparison provided some of the information needed for later design of the cell-targeted pro-drug based on thapsigargin that is now in clinical trials.^{14–16} At the present time all of the commercially available thapsigargin is obtained from intact fruits and roots of *Thapsia garganica* L. plants that are collected from the wild. The potential increasing worldwide demand for thapsigargin is endangering the sparse populations of *T. garganica* and other *Thapsia* species in the Mediterranean area and may lead to their extinction. *Thapsia* and Apiaceae plants in general are difficult to germinate from seed and to maintain under greenhouse conditions.^{13,18} Jäger et al.¹⁹ are the only researchers to have reported the establishment of *in vitro* cultures of *T. garganica* for the purpose of producing thapsigargins. They induced somatic embryos that accumulated two thapsigargins, namely nortrilobolid and trilobolid; the ability to convert somatic embryos into plantlets was not investigated. To date, there has been no report of the successful regeneration of *T. garganica* plantlets *in vitro*.²⁰

Micropropagation of *T. garganica* has also been investigated as an option for conservation purposes as wild populations of the plants are becoming increasingly sparse.¹³ Results show that optimization of *in vitro* propagation of *Thapsia* for large scale production could be very difficult indeed. This is consistent with reports that acclimatization of plants from the Apiaceae family in general is very difficult to achieve.^{18,21} Nevertheless, *in vitro* propagation could serve as a way for the conservation of the medicinally important species, *T. garganica*.²⁰ Another possible method by which thapsigargin could be obtained is by chemical synthesis. However, although thapsigargin can be

chemically synthesized, it is not in any way commercially feasible at the moment.²²

Given the difficulties associated with the supply of thapsigargin from wild plants, the inability to cultivate *Thapsia garganica* efficiently, and the expense of chemical synthesis, an alternative production platform needs to be developed to meet world market demand.^{16,20} Previously, attempts have been made to transfer the sesquiterpene biosynthetic pathway to bacteria or fungi; these have been somewhat successful.¹⁰ Recently the group of J. Keasling reported the successful generation of a yeast strain producing the artemisinin precursor amorphaadiene.² One of the major obstacles for metabolic engineering in microorganisms is to obtain functional expression of P450's. Yeast is generally considered to be a better host for this, owing to its eukaryotic membrane structure.²³ Simple pathways such as the three steps for the formation of amorphaadiene are likely to be successful in yeast, whereas more complex pathways such as the 19 step taxol biosynthesis are much more complex and difficult to predict. With microbial engineering some of the critical elements for stable production are: Choice of host strain, expression level, codon-bias, N-terminal modifications and choice of reduction partners, all of equal importance.^{23,24}

To achieve such success, an in-depth understanding of the original biosynthesis pathway of the target molecule is of great importance. The primary metabolism of terpenes and especially sesquiterpenes is gradually being elucidated and issues such as compartmentation (Fig. 1) have been observed to be of vital importance.^{3,25} When transferring biosynthetic pathways from one kingdom to another, the correct localization of introduced enzymes and other regulation issues can create problems as observed with plant P450s expressed in microorganisms.^{10,23} Although these problems can be overcome as they are encountered, it is possible that they could be avoided by using other host organisms like the moss, *Physcomitrella patens*, or by using cell cultures as is done with Taxol production.¹² Attempts at using yeast strains for the production of amorphaadiene, an artemisinin precursor have been somewhat successful, but for small natural products several obstacles have to be addressed as outlined above. Yeast utilizes several regulatory mechanisms to maintain tight control over the intracellular level of farnesyl diphosphate (FPP), the central precursor to nearly all yeast isoprenoid products and an essential building block for sesquiterpenes.²⁶




Figure 1. Overall sketch of the two IPP/DMAPP producing pathways and their intracellular localization in plants. Arrows indicate the overall pathway; many intermediates and additional substrates such as ATP and NADPH are omitted. The possible crosstalk between pathways is also marked with arrows. GPP: Geranyl diphosphate (C10), FPP: Farnesyl diphosphate (C15), GGPP: Geranylgeranyl diphosphate (C20).^{3,51}

High-level production of non-native terpenoids requires that FPP flux is diverted from production of sterols to the heterologous metabolic pathway. To do so, expression of the gene encoding squalene synthase (ERG9), the first committed step in sterol biosynthesis, can be down-regulated. Under certain culture conditions, the production of amorphaadiene was increased five-fold by ERG9 repression.²⁶ The isoprenoid pathway in the plastid and in the cytosol supplies precursor for mono- and sesquiterpene biosynthesis and an array of other compounds, many of which are crucial to plant growth and fitness such as sterols, gibberellins, carotenoids and chlorophyll.²⁷ Thus, strong and constitutive expression of introduced genes could be most harmful. It is therefore highly recommended in future metabolic engineering experiments to direct gene expression to a specific tissue or organ or use an inducible system, as observed with taxadiene production in *Arabidopsis*.²⁸

The Benefits of the Moss *Physcomitrella Patens*

The moss lineage diverged from vascular plants about 450 million years ago and has maintained a small and rather simple vegetative body structure with few specialized cell types.²⁹ Unlike vascular plants, the haploid gametophyte dominates the life cycle, while the diploid sporophyte is short-lived and completely dependent on the gametophyte.³⁰




Figure 2. The proposed formation of eudesmanolides and guaianolides from costunolide in Chicory.^{49,50}

Physcomitrella patens has been used as a model for studies on plant evolution, development and physiology for more than 40 years. However, the recent release of the full genome sequence has sparked an enormous interest in this plant, which is also increasingly being used in biotechnology for safe production of complex biopharmaceuticals.^{31,32} One example is the production of the highly glycosylated peptide hormone erythropoietin (EPO).³³ Production of EPO was carried out in a *Physcomitrella* Delta-fuc-t Delta-xyl-t strain, deficient in the enzymes responsible for the plant-specific core-bound alpha 1,3-fucose and beta 1,2-xylose. Thus, the final product will have a humanized glycosylation pattern and therefore be non-immunogenic.^{33,34}

Physcomitrella has a number of features that make it an attractive production system when compared with other plant production hosts. *Physcomitrella* can be grown in sterile cultures using standard plant tissue culturing techniques. It grows photoautotrophically in a simple inorganic media without the need for phytohormones, vitamins or a carbon source.³⁵ It can be maintained on solid media or as liquid cultures in flasks or fermenters. Unlike other plant production systems where liquid cultures are normally composed of cells from undifferentiated callus, large continuous *Physcomitrella* cultures can be maintained as

protonema (the haploid phase).³⁶ In contrast to callus cultures, in which undifferentiated cells have a high level of somaclonal variation, a culture consisting of protonema has a stable genetic background, ensuring that the genetic composition of continuous *Physcomitrella* cultures does not change over time.³¹ In addition, *Physcomitrella* has proved to be very tolerant to a number of abiotic stresses.³⁷ This high level of tolerance could ensure that the *Physcomitrella* production strain will be less affected in fitness during the biosynthesis.

The protonemal state can be maintained by continuously splitting the tissue into smaller pieces using a propeller fitted with blades. Cultivation in suspension allows scaling up of biofermenters to several thousand liters and the minimal media, which contains only minerals and water, enables high volume and low cost, and minimizes the risk of contamination. An additional advantage is that unlike any other plant known to date, *Physcomitrella* performs homologous recombination with high efficiency.³⁸ This allows efficient and precise gene deletions, replacements and insertions and permits us to make specific and controlled recombination events that generate transformants with predictable properties. Thus, development of a stable production strain does not require crossing steps or regeneration of whole plants.³⁹ Combined with the Cre-lox technology, high throughput production

strains with a defined background lacking the antibiotic resistance marker can be generated.³⁸ The availability of several characterized constitutive or inducible promoters will further assist in the formation of useful production strains.^{40–42}

Ease of handling, simple life cycle and growth conditions, and the unique molecular tools available for gene targeting make the moss *Physcomitrella* an ideal candidate for the production of natural products that are difficult to access through other means. A potential challenge in the production of high levels of secondary metabolites is secretion into the media. Wild type *Physcomitrella* is able to secrete large amounts of the tetracyclic diterpene, 16 α -hydroxykaurane, which forms needle-like crystal structures when *Physcomitrella* grows on solid media in sealed containers.⁴³ This demonstrates that the capacity exists within *Physcomitrella* for the processing of terpenoid metabolites through secretion of the compound in large quantities. To utilize this pathway one should think of a knock-out the original diterpene production.⁴⁴

Combinatorial Biosynthesis in Moss

Combinatorial biosynthesis has already been successfully employed in micro-organisms for the production of compounds such as novel antibiotics.^{45,46} An *in vivo* combinatorial biosynthesis approach is pursued in *Physcomitrella*, primarily to obtain new and known natural products with useful biological activity. The generation of a moss that produces thapsigargin would add to our library of mutants, and secure a stable supply of chemically related and robust drugs. Following the establishment of such a model of *Physcomitrella patens*, the production of thapsigargin could be further enhanced by utilizing the knowledge of carbon and other important atom fluxes within plant cells.

In addition to thapsigargin and artemisinin, other sesquiterpene lactones are of interest as therapeutics. One such compound is parthenolide, a well-studied sesquiterpene lactone that is the major active compound in the medicinal plant *Tanacetum parthenium* (feverfew) and very promising as a cancer drug.⁴⁷ *Tanacetum parthenium* is currently used as herbal remedy to relieve migraine, to help prevent blood clots, as an anti-inflammatory for relief in cases of arthritis, to relieve some types of menstrual problems, and as a digestive aid.⁴⁸ Interestingly, parthenolide may be one of the precursors for thapsigargin (Fig. 2).^{49,50}

Both artemisinin and thapsigargin are currently obtained by extraction from plants. Given their wide range of potential medical applications, the demand for these compounds is likely to vastly exceed the current levels of the current production. An important additional outcome of this concept is that knowledge obtained during the establishment of a *Physcomitrella* strain producing a thapsigargin precursor will enable the design of several other drug-candidate-producing moss strains, especially within the chemical class of sesquiterpene lactones.

With the results that we currently are verifying in our lab we believe that the first simple structures can be produced within one year, with increasing complexity of the molecules produced in the following years. In conclusion, the possibilities of using *Physcomitrella* as a new production platform for plant-derived natural products are numerous and interesting. While several issues need to be addressed and are currently being so, the future remains promising, and various kinds of natural products could be produced in this simple and easily grown plant.

Disclosure

The authors report no conflicts of interest.

References

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. *J Nat Prod.* 2007;70:461–77.
2. Chang MCY, Keasling JD. Production of isoprenoid pharmaceuticals by engineered microbes. *Nat Chem Biol.* 2006;2:674–81.
3. Barton Sir D, Nakanishi K, Meth-Cohn O. Comprehensive natural products chemistry. Elsevier Science Ltd, London. 1999.
4. Modzelewska A, Sur S, Kumar SK, Khan SR. Sesquiterpenes: Natural products that decrease cancer growth. *Curr Med Chem—Anti-Cancer Agents.* 2005;5:477–99.
5. Evans WC. Trease and Evans' pharmacognosy, 13 ed., London, U.K.: Bailliere Tindal. 1989.
6. Simonsen HT, Larsen MD, Nielsen MW, et al. Methylenedioxy- and methoxyflavones from *Melicope coodeana* syn. *Euodia simplex*. *Phytochem.* 2002;60:817–20.
7. Simonsen HT, Nordskjold JB, Smitt UW, et al. In vitro screening of Indian medicinal plants for antiplasmodial activity. *J. Ethnopharm.* 2001;74:195–204.
8. Rocha ABD, Lopes RM, Schwartzmann G. Natural products in anticancer therapy. *Curr Opin Pharmacol.* 2001;1:364–9.
9. Gordon M Cragg, David J Newman. Plants as a source of anti-cancer agents. *Journal of Ethnopharmacology.* 22 August 2005;100(1–2): 72–79.
10. Withers ST, Keasling JD. Biosynthesis and engineering of isoprenoid small molecules. *Appl Microbiol Biotechnol.* 2007;73:980–90.
11. Withers. Source of New Hope Against Malaria is in Short Supply Martin Enserink Science 7 January 2005;307(5706):33.
12. Phyton Biotech. History. Product information [online]. Accessed on 18 December 2008. URL: <http://www.phytonbiotech.com/>. 2008.

13. Makunga NP, Jäger AK, Van Staden J. Micropropagation of *Thapsia garganica*—a medicinal plant. *Plant Cell Rep.* 2003;21:967–73.
14. Denmeade SR, Jakobsen CM, Janssen S. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. *J Natl Cancer Inst.* 2003;95:990–1000.
15. Janssen S, Rosen DM, Ricklis RM, et al. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. *The Prostate.* 2006;66:358–68.
16. Søhoel H, Jensen AM, Møller JV, et al. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. *Bioorg Med Chem.* 2006;14:2810–15.
17. Toyoshima C, Nomura H. Structural changes in the calcium pump accompanying the dissociation of calcium. *Nature.* 2002;418:605–11.
18. Ekiert H. Medicinal plant biotechnology: the Apiaceae family as an example of development. *Pharmazie.* 2000;55:561–67.
19. Jäger AK, Schottländer B, Smitt UW, et al. Somatic embryogenesis in cell cultures of *Thapsia garganica*: Correlation between the state of differentiation and the content of thapsigargin. *Plant Cell Rep.* 1993;12:517–20.
20. Makunga NP, Jäger AK, Van Staden J. Improved in vitro rooting and hyperhydricity in regenerating tissues of *Thapsia garganica* L. *Plant Cell Tiss Organ Cult.* 2006;86:77–86.
21. Ebrahimie E, Habashi AA, Ghareyazie B, et al. A rapid and efficient method for regeneration of plantlets from embryo explants of cumin (*Cuminum cyminum*). *Plant Cell Tiss Org Cult.* 2003;75:19–25.
22. Ball M, Andrews SP, Wierschem F, et al. Total synthesis of thapsigargin, a potent SERCA pump inhibitor. *Org Lett.* 2007;9:663–6.
23. Kirby J, Keasling JD. Metabolic engineering of microorganisms for isoprenoid production. *Nat Prod Rep.* 2008;25:656–61.
24. Chang MC, Eachus RA, Trieu W, et al. Engineering *Escherichia coli* for production of functionalized terpenoids using plant P450s. *Nat Chem Biol.* 2007;3:274–277.
25. Simonsen HT, Reichwald K, Krichau N (*in press*). Guaianolides in Apiaceae, perspectives on pharmacology and biosynthesis. *Phytochem Rev.*
26. Paradise EM, Kirby J, Chan R, et al. Redirection of flux through the FPP branch-point in *Saccharomyces cerevisiae* by down-regulating squalene synthase. *Biotech Bioeng.* 2008;100:371–78.
27. Aharoni A, Jongsma MA, Kim T-Y, et al. Metabolic engineering of terpenoid biosynthesis in plants. *Phytochem Rev.* 2006;5:49–58.
28. Besumbes O, Sauret-Gueto S, Phillips MA, et al. Metabolic engineering of isoprenoid biosynthesis in *Arabidopsis* for the production of taxadiene, the first committed precursor of taxol. *Biotechnol Bioeng.* 2004;88:168–75.
29. Reski R. Do we need another model plant? *Plant Biol.* 2005;7:219.
30. Reski R. Development, genetics and molecular biology of mosses. *Botanica Acta.* 1998;111:1–15.
31. Decker EL, Reski R. Moss bioreactors producing improved biopharmaceuticals. *Curr opin Plant Biotech.* 2007;18:393–98.
32. Decker EL, Reski R. Current achievements in the production of complex biopharmaceuticals with moss bioreactors. *Bioprocess Biosyst Eng.* 2008;31:3–9.
33. Weise A, Altmann F, Rodriguez-Franco M, et al. High-level expression of secreted complex glycosylated recombinant human erythropoietin in the *Physcomitrella* Delta-fuc-t Delta-xyl-t mutant. *Plant Biotech J.* 2007;5:389–401.
34. Huether CM, Lienhart O, Baur A, et al. Glyco-engineering of moss lacking plant-specific sugar residues. *Plant Biol.* 2005;7:292–9.
35. Ashton NW, Cove DJ. Isolation and preliminary characterization of auxotrophic and analog resistant mutants of moss, *Physcomitrella patens*. *Mol Gen Genet.* 1977;154:87–95.
36. Greenovation. Research information, production information [online]. Accessed 18 December 2008. URL: <http://www.greenovation.de/>. 2008.
37. Frank W, Ratnadewi D, Reski R. *Physcomitrella patens* is highly tolerant against drought, salt and osmotic stress. *Planta.* 2005a;220:384–94.
38. Schaefer DG. A new moss genetics: Targeted mutagenesis in *Physcomitrella patens*. *Annu Rev Plant Biol.* 2002;53:477–501.
39. Frank W, Decker EL, Reski R. Molecular tools to study *Physcomitrella patens*. *Plant Biol.* 2005b;7:220–7.
40. Horstmann V, Huether CM, Jost W, et al. Quantitative promoter analysis in *Physcomitrella patens*: a set of plant vectors activating gene expression within three orders of magnitude. *BMC Biotech.* 2004;4:13.
41. Saidi Y, Finka A, Chakhporanian M, et al. Controlled expression of recombinant proteins in *Physcomitrella patens* by a conditional heat-shock promoter: A tool for plant research and biotechnology. *Plant Mol Biol.* 2005;59:697–711.
42. Lunde C, Drew DP, Jacobs AK, et al. Exclusion of Na⁺ via sodium ATPase (PpENA1) ensures normal growth of *Physcomitrella patens* under moderate salt stress. *Plant Phys.* 2007;144:1786–96.
43. Schwartzberg von K, Schultze W, Kassner H. The moss *Physcomitrella patens* releases a tetracyclic diterpene. *Plant Cell Rep.* 2004;22:780–6.
44. Hayashia K-I, Kawaideb H, Notomib M, et al. Identification and functional analysis of bifunctional ent-kaurene synthase from the moss *Physcomitrella patens*. *FEBS Lett.* 2006;580:6175–81.
45. Weissman KJ, Leadlay PF. Combinatorial biosynthesis of reduced polyketides. *Nature Rev Microbio.* 2005;3:925–36.
46. Piel J. Combinatorial biosynthesis in symbiotic bacteria. *Nat Chem Biol.* 2006;2:661–2.
47. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood.* 2005;105:4163–9.
48. Ernst E, Pittler MH. The efficacy and safety of feverfew (*Tanacetum parthenium* L.): an update of a systematic review. *Public Health Nutr.* 2000;3:509–14.
49. De Kraker JW, Franssen MCR, de Groot A, et al. (+)-Germacrene A biosynthesis—The committed step in the biosynthesis of bitter sesquiterpene lactones in chicory. *Plant Physiol.* 1998;117:1381–92.
50. De Kraker JW, Franssen MCR, Joerink M, et al. Biosynthesis of costunolide, dihydrocostunolide, and leucodin. Demonstration of cytochrome P450-catalyzed formation of the lactone ring present in sesquiterpene lactones of chicory. *Plant Physiol.* 2002;129:257–68.
51. Okada K, Kasahara H, Yamaguchi S, et al. Genetic evidence for the role of isopentenyl diphosphate isomerases in the mevalonate pathway and plant development in *Arabidopsis*. *Plant Cell Phys.* 2008;49:604–16.